Company
Ionis Pharmaceuticals
Ionis Pharmaceuticals has 36 drugs tracked on RxWires: 1 approved, 6 in Phase 3, 15 in Phase 2, 6 in Phase 1/2, 8 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| DAWNZERA (AUTOINJECTOR) | Approved | |
| Olezarsen | Phase 3 | Familial Chylomicronemia Syndrome |
| Inotersen | Phase 3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy |
| obudanersen | Phase 3 | Angelman Syndrome |
| zilganersen | Phase 3 | Alexander Disease |
| ION363 | Phase 3 | Amyotrophic Lateral Sclerosis |
| Eplontersen | Phase 3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) |
| ION-827359 | Phase 2 | Chronic Bronchitis |
| sapablursen | Phase 2 | Phlebotomy Dependent Polycythemia Vera |
| Fomivirsen sodium | Phase 2 | Cytomegalovirus Retinitis |
| ISIS 113715 | Phase 2 | Type 2 Diabetes Mellitus |
| IONIS-FB-Lrx | Phase 2 | Geographic Atrophy |
| ISIS 416858 | Phase 2 | End-stage Renal Disease (ESRD) |
| ION904 | Phase 2 | Hypertension |
| IONIS-PKKRx (ISIS 546254) | Phase 2 | Chronic Migraine |
| IONIS-AGT-LRx | Phase 2 | Chronic Heart Failure With Reduced Ejection Fraction |
| ION775 | Phase 2 | Hypertriglyceridemia |
| ISIS apoC-III Rx | Phase 2 | Hypertriglyceridemia |
| ION224 | Phase 2 | Steatohepatitis, Nonalcoholic |
| ISIS CRP Rx | Phase 2 | Paroxysmal Atrial Fibrillation |
| ISIS 721744 | Phase 2 | Covid19 |
| Isis 420915/GSK 299872 | Phase 2 | Amyloidosis |
| ISIS EIF4E Rx | Phase 1/2 | Non-small Cell Lung Cancer |
| ION337 | Phase 1/2 | Dravet Syndrome |
| ION440 | Phase 1/2 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome |
| ION717 | Phase 1/2 | Prion Disease |
| ION582 | Phase 1/2 | Angelman Syndrome |
| ISIS 14803, peginterferon alfa, ribavirin | Phase 1/2 | Hepatitis C, Chronic |
| IONIS-ENaCRx | Phase 1 | Healthy Subjects |
| BIIB094 | Phase 1 | Parkinson's Disease |
| APOC-III-L-Rx | Phase 1 | Elevated Triglycerides (TG) |
| IONIS FXI-LRx | Phase 1 | Healthy Participants |
| ION269 | Phase 1 | Alzheimer Disease |
| ION547 | Phase 1 | Healthy Volunteers |
| ION464 | Phase 1 | Multiple System Atrophy |
| ISIS 325568 | Phase 1 | Type 2 Diabetes Mellitus |
Latest
- ionis pharmaceuticals filed 8-K
- ionis pharmaceuticals filed 8-K
- Breakthrough Therapy Designation: ionis pharmaceuticals
- ionis pharmaceuticals filed 8-K
- Priority Review: ionis pharmaceuticals
Follow Ionis Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.